AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression
Biotechnology and Bioengineering · 2026-02 · 123 (2) · 273-286
DOI: 10.1002/bit.70111 ↗At a glance
Journal article in Biotechnology and Bioengineering, published online on 2025-11-18. Written by Alaka Mullick and 8 co-authors. Institution: Human Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada. Major MEDLINE topics: Dependovirus, Capsid, Cell Cycle. Cited 3 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: This work was funded by the National Research Council Canada Disruptive Technology Solutions Cell and Gene Therapy challenge program. The NRC publication numbe….
Abstract (original language)
Adeno‐associated virus (AAV) is a promising delivery system for gene therapy. However, current manufacturing of AAV suffers from very low yields compared to other biotherapeutics. The AAV dose per patient ranges between 10 11 and 10 15 viral genomes (vg), requiring an average of 10 to 30 L production/dose. As a consequence, production costs are prohibitive for most indications. Our recent studies revealed that only 10% of the HEK293 cells that have received the AAV encoding DNA produce assembled AAV capsids. This observation prompts the question: Why would cells that have been successfully transfected, be unable to produce AAV. To answer this question, we undertook a detailed study to characterize the two sub‐populations from the same transfection, the cells that were making assembled capsids and those that were not. We found that the two populations had distinct cell cycle profiles, with a block in cell cycle progression characterizing the producer population. RNA‐seq analysis of the two populations reveals differences in the molecular pathways impacted and provides a basis for making changes to improve productivity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Human Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.
- Digital Technologies Research Centre, National Research Council of Canada, Ottawa, Ontario, Canada.
- Department of Bioengineering, McGill University, Montreal, Quebec, Canada.
- Present Address: Gene Therapy Technical Research and Development, F. Hoffmann-La Roche AG, Basel, Switzerland.
ORCID profiles: Alaka Mullick, Amine A Kamen
Funding
- This work was funded by the National Research Council Canada Disruptive Technology Solutions Cell and Gene Therapy challenge program. The NRC publication numbe…
Cite
APA
Mullick, A., Morasse, A., Leclerc, M., Liu, Z., Liu, Q. Y., Leclerc, S., Momcilovic, M., Viau, A., & Kamen, A. A. (2026). AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression. Biotechnology and Bioengineering, 123(2), 273-286. https://doi.org/10.1002/bit.70111
Vancouver
Mullick A, Morasse A, Leclerc M, Liu Z, Liu QY, Leclerc S, et al. AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression. Biotechnology and Bioengineering. 2026;123(2):273-286. doi:10.1002/bit.70111
BibTeX
@article{Mullick2026,
author = {Mullick, Alaka and Morasse, Audrey and Leclerc, Melanie and Liu, Ziying and Liu, Qing Yan and Leclerc, Sonia and Momcilovic, Milica and Viau, Annie and Kamen, Amine A},
title = {AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression},
journal = {Biotechnology and Bioengineering},
year = {2026},
volume = {123},
number = {2},
pages = {273--286},
doi = {10.1002/bit.70111}
}
EUVIMED